Dagmar Riemann
Overview
Explore the profile of Dagmar Riemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moller M, Schutte W, Turzer S, Seliger B, Riemann D
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835567
An important challenge remains in identifying the baseline characteristics of cancer patients who will mostly benefit from immune checkpoint inhibitor (ICI) therapies. Furthermore, biomarkers could help in the choice of...
2.
Jung M, Jung J, Pfeifer J, Hartmann C, Ehrhardt T, Abid C, et al.
Mol Neurobiol
. 2023 Sep;
61(3):1562-1579.
PMID: 37728850
Late-onset Alzheimer's disease (AD) is a complex multifactorial disease. The greatest known risk factor for late-onset AD is the E4 allele of the apolipoprotein E (APOE), while increasing age is...
3.
Riemann D, Turzer S, Ganchev G, Schutte W, Seliger B, Moller M
Biomolecules
. 2023 Feb;
13(2).
PMID: 36830562
In this exploratory prospective observational study on 40 small cell lung cancer (SCLC) patients treated with a combination of chemotherapy and immune checkpoint inhibitors, blood immune cells were characterized by...
4.
Moller M, Turzer S, Ganchev G, Wienke A, Schutte W, Seliger B, et al.
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954354
Although immune checkpoint inhibitor (ICI) therapies have improved the treatment of patients with advanced non-small cell lung cancer (NSCLC), several patients do not achieve durable clinical responses. Biomarkers for the...
5.
Riemann D, Schutte W, Turzer S, Seliger B, Moller M
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33066260
The aim of this study was to investigate the expression of the coinhibitory molecule PD-L1/CD274 in monocytes and dendritic cells (DC) in the blood of lung cancer patients undergoing PD1...
6.
Moller M, Turzer S, Schutte W, Seliger B, Riemann D
J Immunother
. 2019 Oct;
43(2):57-66.
PMID: 31592989
Characterization of host immune cell parameters before and during immunotherapy is expected to identify predictive biomarkers for clinical outcome. We prospectively monitored blood immune cells from 35 patients with advanced...
7.
Massa C, Robins H, Desmarais C, Riemann D, Fahldieck C, Fornara P, et al.
Oncotarget
. 2017 Feb;
8(13):21212-21228.
PMID: 28177902
A major requirement for cancer immunotherapy is the development of biomarkers for prognosis and for monitoring therapy response. In an attempt to evaluate the immune response of renal cell carcinoma...
8.
Geissler K, Fornara P, Lautenschlager C, Holzhausen H, Seliger B, Riemann D
Oncoimmunology
. 2015 May;
4(1):e985082.
PMID: 25949868
Tumor-associated immune cells have been discussed as an essential factor for the prediction of the outcome of tumor patients. Lymphocyte-specific genes are associated with a favorable prognosis in colorectal cancer...
9.
Fu H, Spieler F, Grossmann J, Riemann D, Larisch M, Hiebl B, et al.
Atherosclerosis
. 2014 Dec;
237(2):443-52.
PMID: 25463072
Objectives: Inflammation is essential for atherogenesis. Cholesterol, a cardiovascular risk factor, may activate inflammation in the vessel wall during this process. Cytokine-mediated interactions of human monocytes with vascular smooth muscle...
10.
Riemann D, Hase S, Fischer K, Seliger B
Clin Transl Med
. 2014 Jul;
3:13.
PMID: 24995120
Background: Neutrophil-to-lymphocyte ratio (NLR) has been shown to be a predictor of patients' outcome for several types of malignancies. Findings: Using multicolor flow cytometry we searched for predictive markers to...